Horizon Therapeutics (United States)

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Raymond S. Douglas, George J. Kahaly, Amy Patel et al. · New England Journal of Medicine · 2020 · 656 citations · Full text

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials

George J. Kahaly, Raymond S. Douglas, Robert J. Holt et al. · The Lancet Diabetes & Endocrinology · 2021 · 170 citations

Ophthalmology, Thyroid Disease, Clinical Trials +5

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment

Raymond S. Douglas, George J. Kahaly, Shoaib Ugradar et al. · Ophthalmology · 2021 · 148 citations · Full text

Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers

Loren Laine, Alan Kivitz, Alfonso E. Bello et al. · The American Journal of Gastroenterology · 2011 · 102 citations

Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis

Richard P. Allen, James R. Connor, Keith Hyland et al. · Sleep Medicine · 2008 · 94 citations · Full text

Sleep, Psychiatry, Neurological Disorder +9